# PS-341 in Treating Patients With Metastatic Kidney Cancer

> **NCT00017329** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00017329
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017329, "PS-341 in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00017329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*